Search

Your search keyword '"Oonishi, Ayano"' showing total 14 results
Start Over Author "Oonishi, Ayano"
14 results on '"Oonishi, Ayano"'

3. Early detection of hepatocellular carcinoma in patients with diabetes mellitus

Author

Nouso, Kazuhiro, primary, Furubayashi, Yoshie, additional, Shiota, Shohei, additional, Miyake, Nozomi, additional, Oonishi, Ayano, additional, Wakuta, Akiko, additional, Kariyama, Kazuya, additional, Hiraoka, Atsushi, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Shimada, Noritomo, additional, Ishikawa, Toru, additional, Tada, Toshifumi, additional, Toyoda, Hidenori, additional, and Kumada, Takashi, additional

Published
2019
Full Text
View/download PDF

4. Simple scoring index for early detection of non-B, non-C hepatocellular carcinoma in patients with diabetes mellitus

Author

Kariyama, Kazuya, primary, Nouso, Kazuhiro, additional, Wakuta, Akiko, additional, Oonishi, Ayano, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Hiraoka, Atsushi, additional, Tsuji, Kunihiko, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Ishikawa, Toru, additional, Shimada, Noritomo, additional, and Kumada, Takashi, additional

Published
2019
Full Text
View/download PDF

5. Utility of FIB4-T as a Prognostic Factor for Hepatocellular Carcinoma

Author

Kariyama, Kazuya, primary, Nouso, Kazuhiro, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Hiraoka, Atsushi, additional, Tsuji, Kunihiko, additional, Itobayashi, Ei, additional, Ishikawa, Toru, additional, Wakuta, Akiko, additional, Oonishi, Ayano, additional, Kumada, Takashi, additional, Kudo, Masatoshi, additional, for HCC (RELPEC) Study Group, on behalf of the Real-Life Practice Experts, additional, and fourtyeight Group, HCC, additional

Published
2019
Full Text
View/download PDF

6. Simple screening method for the diagnosis of nonB-nonC hepatocellular carcinoma

Author

Nouso, Kazuhiro, primary, Furubayashi, Yoshie, additional, Shiota, Shohei, additional, Wakuta, Akiko, additional, Oonishi, Ayano, additional, Kariyama, Kazuya, additional, Takeuchi, Yasuto, additional, Wada, Nozomu, additional, Onishi, Hideki, additional, Adachi, Takuya, additional, Oyama, Atsushi, additional, Dohi, Chihiro, additional, Yasunaka, Tetsuya, additional, Yasunaka, Yuki, additional, Ikeda, Fusao, additional, Shiraha, Hidenori, additional, Takaki, Akinobu, additional, and Okada, Hiroyuki, additional

Published
2018
Full Text
View/download PDF

7. EZ-ALBI Score for Predicting Hepatocellular Carcinoma Prognosis.

Author

Kariyama, Kazuya, Nouso, Kazuhiro, Hiraoka, Atsushi, Wakuta, Akiko, Oonishi, Ayano, Kuzuya, Teiji, Toyoda, Hidenori, Tada, Toshifumi, Tsuji, Kunihiko, Itobayashi, Ei, Ishikawa, Toru, Takaguchi, Koichi, Tsutsui, Akemi, Shimada, Noritomo, Kudo, Masatoshi, and Kumada, Takashi

Subjects
LIVER function tests, HEPATOCELLULAR carcinoma, ALBUMINS, BILIRUBIN, EVALUATION
Abstract

Introduction: The ALBI score is acknowledged as the gold standard for the assessment of liver function in patients with hepatocellular carcinoma (HCC). Unlike the Child-Pugh score, the ALBI score uses only objective parameters, albumin (Alb) and total bilirubin (T.Bil), enabling a better evaluation. However, the complex calculation of the ALBI score limits its applicability. Therefore, we developed a simplified ALBI score, based on data from a large-scale HCC database.We used the data of 5,249 naïve HCC cases registered in eight collaborating hospitals. Methods: We developed a new score, the EZ (Easy)-ALBI score, based on regression coefficients of Alb and T.Bil for survival risk in a multivariate Cox proportional hazard model. We also developed the EZ-ALBI grade and EZ-ALBI-T grade as alternative options for the ALBI grade and ALBI-T grade and evaluated their stratifying ability. Results: The equation used to calculate the EZ-ALBI score was simple {[T.Bil (mg/dL)] – [9 × Alb (g/dL)]}; this value highly correlated with the ALBI score (correlation coefficient, 0.981; p < 0.0001). The correlation was preserved across different Barcelona clinic liver cancer grade scores (regression coefficient, 0.93–0.98) and across different hospitals (regression coefficient, 0.98–0.99), indicating good generalizability. Although a good agreement was observed between ALBI and EZ-ALBI, discrepancies were observed in patients with poor liver function (T.Bil, ≥3 mg/dL; regression coefficient, 0.877). The stratifying ability of EZ-ALBI grade and EZ-ALBI-T grade were good and their Akaike's information criterion values (35,897 and 34,812, respectively) were comparable with those of ALBI grade and ALBI-T grade (35,914 and 34,816, respectively). Conclusions: The EZ-ALBI score, EZ-ALBI grade, and EZ-ALBI-T grade are useful, simple scores, which might replace the conventional ALBI score in the future. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

8. Treatment of Intermediate-Stage Hepatocellular Carcinoma in Japan: Position of Curative Therapies

Author

Kariyama, Kazuya, Nouso, Kazuhiro, Wakuta, Akiko, Oonishi, Ayano, Toyoda, Hidenori, Tada, Toshifumi, Hiraoka, Atsushi, Tsuji, Kunihiko, Itobayashi, Ei, Ishikawa, Toru, Takaguchi, Koichi, Tsutsui, Akemi, Shimada, Noritomo, and Kumada, Takashi

Abstract

Background:Transcatheter arterial chemoembolization (TACE) is the standard therapy for intermediate-stage (IM) hepatocellular carcinoma (HCC). However, IM-HCC includes various clinical conditions, and various therapies were conducted in practice. In this study, we retrospectively analyzed the actually conducted treatments for IM-HCC and their efficacies to elucidate the treatment strategies suitable for IM-HCC. Methods:This study included 627 IM-HCC of 5,260 HCC from 9 hospitals. We examined the treatment strategies of these patients and analyzed the efficacy of each therapy with the Cox proportional hazard model and propensity score-matched analysis. Results:Liver resection, radiofrequency ablation (RFA), and TACE were performed in 165, 108, and 351 patients, respectively. Liver resection and RFA were preferably selected in cases of Barcelona Clinic Liver Cancer (BCLC)-B1/B2, and patient survival was significantly longer than in those treated with TACE (p< 0.0001). However, no beneficial effect of these active therapies was observed in cases of BCLC-B3/B4. Multivariate analysis revealed that surgical resection (hazard ratio = 0.384) and RFA (hazard ratio = 0.597) were negative risk factors for survival. Propensity score-matching analysis revealed that ­survival of RFA-treated patients was longer than that of TACE-treated patients (p= 0.036). Conclusion:RFA and surgical resection were effective for IM-HCC, particularly in BCLC-B1/B2 cases.

Published
2020
Full Text
View/download PDF

13. A case of hepatic sarcoidosis mimicking bile duct cancer

Author

Oonishi, Ayano, primary, Sasaki, Yoshiko, additional, Kutuna, Shigeru, additional, Kawamura, Tomoe, additional, Takechi, Shunji, additional, Ohno, Yoshinori, additional, Yokota, Tomoyuki, additional, Joko, Kouji, additional, and Ohshiro, Yumi, additional

Published
2013
Full Text
View/download PDF

14. [EB virus].

Author

Oonishi A and Kariyama K

Subjects
Antibodies, Viral immunology, Antiviral Agents therapeutic use, Hepatitis virology, Herpesvirus 4, Human isolation & purification, Humans, Viral Vaccines therapeutic use, Epstein-Barr Virus Infections diagnosis, Epstein-Barr Virus Infections drug therapy, Epstein-Barr Virus Infections epidemiology
Published
2015

Catalog

Books, media, physical & digital resources
See catalog results